Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML

Clinical trial NCT07259707 · RECRUITING

Trial details

NCT number: NCT07259707
Sponsor: First Affiliated Hospital of Zhejiang University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia FLT3 Internal Tandem Duplication Positive Intermediate Risk Acute Myeloid Leukemia Fit Patients

Start date: 2026-01-25
Primary completion: 2028-12-31
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.